ANZCTR search results

Preliminary findings suggest aspirin may slow or reduce the rise in core temperature during exercise, improving exercise capacity in individuals with multiple sclerosis (MS). These findings are questionable as the mechanism of action of aspirin does not play any role in active heat production. Cooling interventions like cold water immersion prior to exercise can mitigate heat-related reductions in exercise capacity in individuals with MS. However, many of these interventions are impractical. This project aims to assess the effectiveness of aspirin and skin cooling with a cold water spray on exercise capacity and postural sway in the heat in individuals with MS. It is hypothesised that in individuals with MS, cooling the skin with a cold water spray during exercise, but not ingesting aspirin prior to exercise, will improve exercise capacity and reduce postural sway in the heat.

Heart attack is a major cause of death within the Australian community. Cholesterol blockages in the coronary arteries (the vessels supplying oxygen & nutrients to the heart muscle) are typically responsible for the heart attacks and best seen on a specialized X-ray test that involves injecting dye into these arteries (coronary angiography). Surprisingly, in approximately 10% of heart attack patients, angiography does not show any significant cholesterol blockages. This group of patients is referred to as MINOCA (Myocardial Infarction with NonObstructive Coronary Arteries). The question then arises as to what caused the heart attack in these MINOCA patients? Potential causes include cholesterol plaque rupture, coronary artery spasm or abnormal constriction of the coronary microscopic vessels (coronary microvascular dysfunction). The aim of this study is to determine how often patients with MINOCA have evidence of cholesterol plaques or coronary microvascular dysfunction. Understanding how often these occur and their relationship to heart muscle damages (as seen on cardiac MRI) and symptoms will assist us in developing future treatments for this condition. The microvascular dysfunction assessments and plaque composition assessments will be performed following the standard coronary angiogram procedure and cardiac MRI will be performed within 5 days of the initial admission. All participants will be given informed consent prior to the study participation.

The purpose of the study is to investigate the effects of short-term imposed blur (optical defocus) on central and peripheral length and the vascular layer of the eye ( choroid) that may help to predict that an optical intervention can control myopia progression.

With an increasing prevalence of people with CHD, combined with a lack of data to characterise the full spectrum of cases or long-term outcomes, there is a critical need to understand the burden of CHD in Australia and New Zealand. The development of a Regional Registry can generate the knowledge needed to better understand the true diversity of outcomes and burden of the entire spectrum of CHD across the lifespan. This information has the potential to drive policy development for the optimal management of both paediatric and adult populations to achieve better health outcomes. This Registry will aim to capture data on patients diagnosed with a congenital heart defect at any age and will be conducted in congenital heart units throughout Australia and New Zealand. It will collect data from medical records on epidemiology, CHD history, clinical course, symptoms and burden of disease from all participants who were born with a CHD. By participating in the Registry, hospitals will be able to provide patients with CHD an opportunity to contribute to the body of knowledge about the burden of CHD. This Regional CHD Registry will become a mandatory tool to provide best care to a growing population.

The purpose of this study is to see whether the use of a particular type of PET scan will improve detection rates of cancer, and improve treatment management. Who is it for? You may be eligible for this study if you are aged over 18 and have been referred for radiotherapy after a prostatectomy. Study details All participants in this study will be required to undergo a PET/CT scan and a diagnostic CT Chest/Abdomen Pelvis You will also be asked to fill out a quality of life Questionnaire. before and after commencing radiotherapy. You will be reviewed as part of your routine care with a routine blood test which will monitor your PSA levels at these visits you will be asked to complete a quality of life Questionnaire. It is hoped this research will determine if the use of PET scanning in treatment planning and how it influences radiation treatment planning in patients will improve treatment outcomes for patients with prostate cancer.

This study will profile the gut and the oral microbiome of highly trained athletes before and after a 21-d block of intensified training to determine if changes in the community profile occur with highly controlled exposure to three different training diets (high-carbohydrate [CHO], high-fat low-CHO, and a periodised diet combining high- and low-CHO). The aim of this study is to profile the normal gut and oral microbiome of highly-trained athletes and determine if changes in diet result in concomitant change in gut microbiome community in this population, dependant on the type of diet followed. We hypothesise that the change in dietary pattern along with intensified training will have a pronounced impact on the oral and stool microbial communities.

The aim of the research is to evaluate the feasibility and preliminary efficacy of a 3-month eHealth intervention for women (aged 18-45 years) with a history of pre-eclampsia (within 4 years of diagnosis). Participants (n=90) will be randomly allocated to the intervention (Be Healthe for your Heart) or the control group. Be Healthe for your Heart supports participants to make changes to key lifestyle behaviours associated with cardiovascular risk, using evidence-based behaviour change techniques (e.g. self-monitoring, goal setting). The Be Healthe for your Heart program resources are tailored to women of childbearing age and delivered via website and email newsletters. Outcomes will be measured at baseline and 3-months, including the Framingham Cardiovascular Disease 30-year risk score, cardiovascular disease risk markers (BMI, waist circumference, blood pressure, biochemical markers), lifestyle risk factors (dietary intake, physical activity, stress levels) and general health and well-being. Intervention acceptability will be evaluated using objective usage data and intervention participant feedback via a process evaluation questionnaire.

A recent study has shown that pre-operative carbohydrate loading in adults undergoing laparoscopic surgery can reduce symptoms of nausea, vomiting and pain. A similar trial on the effect of pre-operative carbohydrate loading in children has not been conducted. Our trial aims to determine if pre-operative carbohydrate loading in children has a positive effect on post-operative recovery.

The primary aim of this study is to derive prediction models from baseline variables from the biological and psychosocial domains to identify responders and non-responders to the UPLIFT program. The secondary aim is to gain insight into what characteristics from the biological and psychosocial domains change following completion of the UPLIFT program and at 6 months follow-up. Considering the patient population referred to the program and the characteristics of the UPLIFT program, we hypothesise that the prediction model for success will include baseline variables such as high fear avoidance behaviours, low pain self-efficacy and matched treatment expectations. We hypothesise that the prediction model for non-success will include baseline variables such as high pain catastrophising, high perceived injustice and high scores on the disability and anxiety stress scale. We hypothesise that the derived prediction models will be significantly better at predicting responders and non-responders than the current 55%:45% ratio for treatment success versus non-success from pilot data.

A Phase 1, randomized, 0pen-label study of the relative bioavailability and effect of food on the pharmacokinetics of a novel formulation of PRN2246 compared to a reference formulation. The study will be performed at a single-centre in healthy adult participants. This is a complete-crossover study where each participant will receive all three treatments.